Login to Your Account



Can Protocols Catch Up?

Unbiased Sequencing Speed, Price Now Realistic For Clinic

By Anette Breindl
Science Editor

Monday, December 5, 2011

Testing for specific mutations has already entered the clinical oncology landscape. Cancer drugs such as Zelboraf (vemurafenib, Roche AG and Daiichi Sankyo Co. Ltd.) and Xalkori (crizotinib, Pfizer Inc.) target patients with specific mutations. Earlier in development, some clinical trials, such as for Exelixis Inc.'s cabozantinib, have focused on specific mutations across a variety of tumor types.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription